Personalis (NASDAQ:PSNL) Shares Up 9.1% - Still a Buy?

Key Points

• Shares of Personalis, Inc. rose by 9.1% during mid-day trading, reaching a last traded price of $9.31.
• Equities analysts maintain a mixed outlook, with Weiss Ratings issuing a "sell" rating, while HC Wainwright reaffirmed a "buy" rating with a price target of $8.50.
• Personalis reported a negative net margin of 113.70% and negative earnings per share of ($0.23) for the last quarter, slightly beating analyst expectations.

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) shot up 9.1% during mid-day trading on Thursday . The stock traded as high as $8.97 and last traded at $9.31. 427,516 shares changed hands during trading, a decline of 59% from the average session volume of 1,035,262 shares. The stock had previously closed at $8.53.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a report on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and issued a $8.50 price target on shares of Personalis in a report on Monday, September 8th. BTIG Research set a $6.00 price target on shares of Personalis in a report on Wednesday, August 6th. Finally, Wall Street Zen raised shares of Personalis from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Personalis has an average rating of "Moderate Buy" and an average price target of $7.42.

Personalis Price Performance

The stock has a market capitalization of $849.97 million, a PE ratio of -7.52 and a beta of 1.83. The business's fifty day moving average price is $5.83 and its two-hundred day moving average price is $5.35.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC acquired a new position in Personalis during the third quarter valued at $66,000. Howland Capital Management LLC raised its position in shares of Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock worth $1,872,000 after acquiring an additional 2,500 shares during the period. Man Group plc acquired a new position in shares of Personalis in the second quarter worth about $324,000. BNP Paribas Financial Markets raised its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after acquiring an additional 5,177 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Personalis by 10.5% in the second quarter. Bank of America Corp DE now owns 222,011 shares of the company's stock worth $1,456,000 after acquiring an additional 21,009 shares during the period. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.